Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan

BACKGROUND: The WHO recommends the use of bedaquiline (BDQ) in longer, as well as shorter, multi-drug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is now emerging. We aimed to describe the characteristics of patients in Karakalpakstan, Uzbekistan, who were treated f...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, P., Hasan, T., Zaw, K. K., Allamuratova, S., Ismailov, A., Mendonca, P., Bekbaev, Z., Parpieva, N., Singh, J., Sitali, N., Bermudez-Aza, E., Sinha, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272738/
https://www.ncbi.nlm.nih.gov/pubmed/35768925
http://dx.doi.org/10.5588/ijtld.21.0631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272738/
https://www.ncbi.nlm.nih.gov/pubmed/35768925
http://dx.doi.org/10.5588/ijtld.21.0631

Ejemplares similares